Inventories, Net

9 Months Ended

Sep. 30, 2021

Inventory Disclosure [Abstract]

Inventories, net

4. Inventories, net

The following table presents inventories, net (in thousands):

	September 30, 2021		December 31, 2020
Raw materials	$	30,332	$	25,121
Work-in-process		9,956		30,293
Finished goods		27,009		8,275
Total	$	67,297	$	63,689

As of September 30, 2021 and December 31, 2020, included in finished goods inventory was $22.2 million and $6.7 million of HEPLISAV-B inventory, respectively. The remaining balance in finished goods inventory was CpG 1018. There was no CpG 1018 balance within raw materials and work-in-process inventory as of September 30, 2021 and December 31, 2020.

We recorded prepaid manufacturing costs related to prepayments made to third-party manufacturers of CpG 1018 adjuvant, of $109.8 million and $29.4 million as of September 30, 2021 and December 31, 2020, respectively. We expect these costs to be converted into inventory within the next twelve months.